Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aclaris Therapeutics Inc.

www.aclaristx.com

Latest From Aclaris Therapeutics Inc.

ParaGard TV Spot Misrepresents Contraceptive’s Risks, US FDA Says

‘Untitled’ letter is FDA's third in the past eighteen months to target promotions for women’s health products. In the case of advertisement for CooperSurgical's copper-containing intrauterine device, which is regulated as a drug, the agency took issue with distracting visuals and reliance on superimposed text.

Advertising, Marketing & Sales Ad Complaints

Eskata Video Ad Broadcast On The View Gets Rebuke From US FDA

Agency says superimposed text about risks and efficacy is overshadowed by "attention-grabbing before-and-after photographs" of patients treated with the seborrheic keratoses treatment.

Advertising, Marketing & Sales FDA

Forging Ahead In Vitiligo: Incyte’s Ruxolitinib Cream Scores Phase II Win

The topical version of Jakafi will move into Phase III later this year for the autoimmune disease after a strong Phase II showing.

Clinical Trials Immune Disorders

First Phase III Results Keep Pfizer's Abrocitinib Among JAK Leaders In Atopic Dermatitis

Pfizer follows Lilly as the second company to report positive top-line Phase III results in AD for a JAK inhibitor. Safety is a key concern for the class, but Pfizer did not provide any details about abrocitinib's side effects.

Clinical Trials Dermatology
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
  • Therapeutic Areas
  • Dermatology
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Aclaris Therapeutics Inc.
  • Senior Management
  • Neal Walker, MD, Pres. & CEO
    Frank Ruffo, CFO & Treasurer
    Stuart D Shanler, MD, CSO
    Christopher Powala, COO
    Brett Fair, SVP, Commercial Operations
    Kevin Scott, VP, Sales
  • Contact Info
  • Aclaris Therapeutics Inc.
    Phone: (484) 324-7933
    640 Lee Rd., Ste. 200
    Wayne, PA 19087
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register